Advertisement
Advertisement
HROW
Harrow, Inc. Common Stock
26.89
USDSponsored
+0.85
+3.26%
Nov 06, 15:59 UTC -5
Closed
After-Market
26.89
0.00
-0.02%
Harrow, Inc. Common Stock (HROW) Earnings
HROW Earnings Reports
Positive Surprise Ratio
HROW beat 12 of 35 last estimates.
34%
Next Report
Today AMC
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$100.47M
/$0.22
Implied change from Q2 26 (Revenue/ EPS)
+42.19%
/-147.83%
Implied change from Q3 25 (Revenue/ EPS)
+40.25%
/--
Harrow, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, HROW reported earnings of -0.46 USD per share (EPS) for Q2 26, missing the estimate of -0.18 USD, resulting in a -150.54% surprise. Revenue reached 70.66 million, compared to an expected 71.75 million, with a -1.52% difference. The market reacted with a -3.15% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of 0.22 USD, with revenue projected to reach 100.47 million USD, implying an decrease of -147.83% EPS, and increase of 42.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Harrow, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Harrow, Inc. Common Stock reported EPS of -$0.46, missing estimates by -150.54%, and revenue of $70.66M, -1.52% below expectations.
How did the market react to Harrow, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -3.15%, changed from $40.70 before the earnings release to $39.42 the day after.
When is Harrow, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Harrow, Inc. Common Stock's next earnings report?
Based on 8
analysts, Harrow, Inc. Common Stock is expected to report EPS of $0.22 and revenue of $100.47M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.